Last reviewed · How we verify
NCT01472003
An Evaluation of the Biodistribution and Imaging Characteristics of ABT-806i (111In-ABT-806) in Subjects With Advanced Solid Tumor Types Likely to Express Epidermal Growth Factor Receptor (EGFR)
Phase 1 trial testing ABT-806 in Advanced Solid Tumors in 18 participants. Completed in 1 December 2012.
1 December 2012
Quick facts
| Lead sponsor | AbbVie (prior sponsor, Abbott) |
|---|---|
| Phase | Phase 1 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | single group |
| Masking | none |
| Primary purpose | diagnostic |
| Enrollment | 18 |
| Start date | 1 October 2011 |
| Primary completion | 1 December 2012 |
| Estimated completion | 1 December 2012 |
| Sites | 2 locations across Australia |
Drugs / interventions tested
Conditions studied
- Advanced Solid Tumors — all drugs for Advanced Solid Tumors →
Sponsor
AbbVie (prior sponsor, Abbott) — full company profile →
Who can join
18 and older, any sex, with Advanced Solid Tumors. Patients with the condition only — healthy volunteers not accepted.
What's being measured
Primary outcomes are the specific endpoints the trial is designed to prove or disprove.
-
Single-Photon Emission Computerized Tomography (SPECT)
Time frame: Week 1
Tumor receptor occupancy (Cohort 1 and Cohort 2) -
Single-Photon Emission Computerized Tomography (SPECT)
Time frame: Week 6
Tumor receptor occupancy (Cohort 2) -
Whole body planar imaging
Time frame: Week 1
Biodistribution and dosimetry (Cohort 1 and Cohort 2) -
Whole body planar imaging
Time frame: Week 6
Biodistribution and dosimetry (Cohort 2)
Sponsor's own description
This is an open label study designed to evaluate the biodistribution and imaging characteristics of ABT-806i (111In-ABT-806) in subjects with advanced solid tumor types.
Publications & conference data
4 peer-reviewed publications reference this trial (live from Europe PMC):
-
EGFR, the Lazarus target for precision oncology in glioblastoma.
Lin B, Ziebro J, Smithberger E, Skinner KR, et al · · 2022 · cited 34× · PMID 36125064 · DOI 10.1093/neuonc/noac204 -
Prospects of biological and synthetic pharmacotherapies for glioblastoma.
Altshuler DB, Kadiyala P, Nuñez FJ, Nuñez FM, et al · · 2020 · cited 13× · PMID 31959027 · DOI 10.1080/14712598.2020.1713085 -
Recent Advances in Glioma Cancer Treatment: Conventional and Epigenetic Realms.
Karami Fath M, Babakhaniyan K, Anjomrooz M, Jalalifar M, et al · · 2022 · cited 12× · PMID 36146527 · DOI 10.3390/vaccines10091448 -
The Evolving Paradigm of Antibody-Drug Conjugates Targeting the ErbB/HER Family of Receptor Tyrosine Kinases.
High P, Guernsey C, Subramanian S, Jacob J, et al · · 2024 · cited 8× · PMID 39065587 · DOI 10.3390/pharmaceutics16070890
Verify or expand the search:
- PubMed search for NCT01472003
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of ABT-806
Trials testing the same drug.
- NCT02213289 — PANGEA-IMBBP: Personalized Antibodies for Gastro-Esophageal Adenocarcinoma - A 1st Pilot Metastatic Trial of Biologics B · Phase 2 · completed
Other recruiting trials for Advanced Solid Tumors
Currently open trials in the same condition.
- NCT07504445 — Clinical Study on the Efficacy and Safety of CAR-DC in the Treatment of Advanced Solid Tumors · EARLY_PHASE1 · recruiting
- NCT07589530 — Phase 1/2 Study of EB-NK-301 (Allogeneic TROP2-CAR NK Cells) in Advanced TROP2-Expressing Solid Tumors · Phase 1, PHASE2 · recruiting
- NCT07360314 — Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors · Phase 1 · recruiting
- NCT07414316 — A Single-Arm, Open-Label Clinical Study GK01 Cell Injection in Subjects With Advanced Solid Tumors. · EARLY_PHASE1 · recruiting
- NCT07222969 — A Clinical Study to Evaluate the Safety of VIB305 in Patients With Advanced Solid Tumors · Phase 1, PHASE2 · recruiting
Other AbbVie (prior sponsor, Abbott) trials
Trials by the same sponsor.
- NCT01609933 — A Study to Evaluate the Safety and Effect of Treatment With Experimental Antiviral Drugs in Combination With Peginterfer · Phase 2 · completed
- NCT01657799 — Comparison of Veliparib and Whole Brain Radiation Therapy (WBRT) Versus Placebo and WBRT in Adults With Brain Metastases · Phase 2 · completed
- NCT01736189 — Assessment of Clinical Effectiveness and Safety of Adalimumab and High Dose Methotrexate in Routine Clinical Practice · completed
- NCT01620528 — A Clinical Study to Evaluate the Safety and Efficacy of Elagolix in Subjects With Moderate to Severe Endometriosis-Assoc · Phase 3 · completed
- NCT01506947 — A Pilot Clinical Study Evaluating the Effect of Parathyroid Hormone (PTH) Lowering On Erythropoietin Consumption in Calc · Phase 4 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT01472003 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by AbbVie (prior sponsor, Abbott)
- Last refreshed: 10 January 2013
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01472003.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing